2-mercaptopropionylglycin (2-MPG), a cell membrane penetrating thiol, was evaluated for its antithrombotic potential using in vitro and in vivo tests. 2-MPG was found to inhibit agonist-induced platelet aggregation and serotonin release as well as prostaglandin/thromboxane synthesis in platelet-rich plasma. Administration of 2-MPG to rats resulted in an inhibition of laser-induced thrombus formation in mesenteric vessels. When plasma was incubated with 2-MPG and then used for determination of various standard coagulation parameters, significant prolongation of the clotting times were observed.
Download full-text PDF |
Source |
---|
ACS Appl Bio Mater
March 2025
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow 226025, India.
Multidrug resistance (MDR) infectious wounds are a major concern due to drug resistance, leading to increased patient morbidity. Lichenysin (LCN), a lipopeptide and biosurfactant obtained from certain strains of , has demonstrated an excellent antimicrobial property. The present study focuses on the fabrication and comprehensive evaluation of LCN-incorporated poly(vinyl alcohol) (PVA)/polycaprolactone (PCL)-based nanofiber scaffolds using an electrospinning technique as a potential wound healing biomaterial for the treatment of MDR infectious wounds in diabetic rats.
View Article and Find Full Text PDFJ Ethnopharmacol
March 2025
Fundação Educacional do Município de Assis (FEMA), Assis, São Paulo, Brazil.
J Genet Eng Biotechnol
March 2025
Centre for Bioinformatics, M.D. University, Rohtak, Haryana, India. Electronic address:
The emergence of multidrug resistanceagainst several antifungal drugs and the absence of alternate therapy limits the treatment choices leading to the spread of Candida auris infections, especially inimmunocompromised patients. This work aims to construct the multi-epitope vaccine using an immuno-informatics approachdue to the lack of efficient treatments for C. auris.
View Article and Find Full Text PDFJ Immunother Cancer
March 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.
View Article and Find Full Text PDFCell Signal
March 2025
Traditional Chinese Medicine Integrated Department of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China; Research Institute of Nephrology, Zhengzhou University, Zhengzhou 450052, PR China; Henan Province Research Center for Kidney Disease, Zhengzhou 450052, PR China; Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou 450052, PR China; Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University Zhengzhou, Henan, China; Innovation Center of Basic Research for Metabolic-Associated Fatty Liver Disease, Ministry of Education of, China. Electronic address:
Acute kidney injury (AKI) lacks a definitive therapeutic approach beyond supportive care. One significant pathological mechanism involves the regulated death of tubular epithelial cells; however, the regulatory mechanisms underlying this cell death pathway require further investigation. The N6-methyladenosine (m6A) modification, recognized as the most prevalent modification in eukaryotes, plays a critical role in the regulatory processes associated with AKI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!